疏血通联合低分子右旋糖酐治疗进展性脑梗死疗效观察  

Applicative study on efficacy of Shuxuetong combined with dextran 40 on progressive cerebral infarction

作　　者：张淑静 

机构地区：[1]河北迁西县中医院脑内科,迁西064300

出　　处：《中国实用神经疾病杂志》2014年第6期31-32,共2页Chinese Journal of Practical Nervous Diseases

摘　　要：目的对疏血通注射液联合低分子右旋糖酐治疗进展性脑梗死的有效性及安全性进行评价。方法收集2011-11—2012-10就诊于我院诊断为进展性脑梗死患者,随机分为治疗组与对照组,除给予必要的抗血小板、抗凝等基本治疗外,治疗组加用疏血通及低分子右旋糖酐联合治疗,对照组仅加用低分子右旋糖酐治疗。结果治疗组有效率为81.67%,对照组为58.33%,2组比较差异具有统计学意义(P<0.05);2组治疗后与治疗前相比PT延长,APTT延长,FIB水平下降,差异有统计学意义(P<0.05),但治疗后2组比较差异无统计学意义(P>0.05),所有患者均未出现药物不良反应。结论疏血通注射液联合低分子右旋糖酐具有起效快、疗效显著、安全性高等特点,能够提高进展性脑梗死患者的治愈率与有效率,具有临床推广价值。Objective To evaluate the efficacy and safety of Shuxuetong combined with dextran 40 on progressive cerebral infarction. Methods patients in hospital who were diagnosed as progressive cerebral infarction from November 2009 to October 2012 were divided into 2 groups-treatment group and control group randomly. Both groups were treated with antiplatelet, anti- coagulation and other basic therapy. Besides these, treatment group were given Shuxuetong combined with dextran 40 while control group were given only dextran 40. Results Clinical effective rate of treatment group was 81.67% while 58.33 in con- trol group, the difference statistical s ignificant（P〈0.05）. As PT, APTT raise and FIB falls, blood coagulation function were improved after treatment in both groups respectively（P〈0.05）, with no statistical significance between 2 groups however. And no patients were found to suffer adverse drug effects. Conclusion Due to great efficacy and safety, Shuxuetong combined with Dextran 40 can improve the recovery rate and effective rate of patients with progressive cerebral infarction, which makes it de- serve widespread clinical appliance.

关 键 词：疏血通注射液 低分子右旋糖酐 进展性脑梗死 DEXTRAN 40 

分 类 号：R743.33[医药卫生—神经病学与精神病学]